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Abstract 
Chronic airway inflammatory diseases are characterised by persistent proinflammatory 
responses in the respiratory tract. Although, several treatment strategies are currently 
available, lifelong therapy is necessary for most of these diseases. In recent years, 
phytophenols, namely, flavonoids, derived from fruits and vegetables have been gaining 
tremendous interest and have been extensively studied due to their low toxicological profile. 
Naringenin is a bioflavonoid abundantly found in citrus fruits. This substance has shown 
notable therapeutic potential in various diseases du  to its promising diverse biological 
activities. In this review, we have attempted to review the published studies from the 
available literature, discussing the molecular level m chanisms of naringenin in different 
experimental models of airway inflammatory diseases including asthma, chronic obstructive 
pulmonary disease (COPD), lung cancer, pulmonary fib osis and cystic fibrosis. Current 
evidences have proposed that the anti-inflammatory properties of naringenin play a major 
role in ameliorating inflammatory disease states. In addition, naringenin also possesses 
several other biological properties. Despite the proposed mechanisms suggesting remarkable 
therapeutic benefits, the clinical use of naringenin is, however, hampered by its low solubility 
and bioavailability. Furthermore, this review also discusses on the studies that utilise 
nanocarriers as a drug delivery system to address th  i sue of poor solubility.  
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1.1. Chronic airway inflammatory diseases 
Chronic airway inflammatory diseases are long-term pathological conditions affecting the 
respiratory system and the structures associated to it. With the continual advancements in 
Science, humans have been, from time immemorial, striving to discover effective therapies 
for such diseases. Nevertheless, there is a steady rise in the number of people who are newly 
affected from such diseases each year, leading to an immense global health burden. The most 
common chronic airway inflammatory diseases are, asthma, chronic obstructive pulmonary 
disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis. There already exists a 
large body of research and extensive published literature on these diseases (Mehta et al., 
2019a), leading to several significant ground-breaking scientific advancements.  
Currently, there are over 358 million people who are globally affected by asthma alone. 
However, it has been predicted that, by the year 2025, this number may jump up to 400 
million (Mehta et al., 2019b; Soriano et al., 2017). In a similar vein, the global prevalence of 
COPD was estimated to be a staggering 251 million cases, as reported by the ‘2016 Global 
Disease Burden Study’ (Soriano et al., 2017). Among the major chronic respiratory diseases, 
lung cancer continues to remain as the leading cause of cancer-related deaths in humans 
(Barta et al., 2019). It is reported that, more than a billion people on the face of earth are 
exposed to polluted air and tobacco smoke, which are key detrimental factors directly 
associated with the mortality and incidences of lung cancer (Jemal et al., 2010; Thun et al., 
2013; Youlden et al., 2008). Pulmonary fibrosis, a rel tively rare form of chronic respiratory 
inflammatory disease is reported with an incidence rat of 7-16 cases per 100,000 population 
(Raghu et al., 2006). Cystic fibrosis, on the other and has an incidence rate of 20 cases per 
100,000 live births, as reported in a study conducted in California, among 2,282,138 new-
borns between the years 2005 to 2010 (Spoonhower and D vis, 2016). 
Airway inflammation is a complex and complicated biological reaction that occurs as a 
defensive response, to protect body tissues. The entir  process primarily involves various 
immune cells as well as, several molecular mediators. It is well known that inflammation is 
initiated when several reactive oxygen species (ROS) are formed during bodily defence 
mechanisms against invasion of pathogens in the respiratory tract (Mittal et al., 2014). 
Inflammation in any respiratory tissues will attract other inflammatory cells, after exposure to 
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oxidants, which eventually favour oxidative stress in the lungs. These myriad of reactions and 
processes lead to sustained inflammation and eventually chronic oxidative stress (Kirkham 
and Barnes, 2013).  
1.2. Naringenin  
For several decades now, the biological activities and therapeutic benefits of flavonoids 
have been gaining much interest in several diseases (Wilcox et al., 1999). In order to study 
their prospective impacts, many active compounds from various forms of folk medicine were 
separated and studied in detail. In the past few years, several experimental and clinical 
studies have also been conducted on polyphenols. Naringenin is a therapeutic flavone, which 
has gained attention in recent years from among them. It is a common active compound that 
is present in various citrus fruits, which include, grapefruit, orange and lemon (Zaidun et al., 
2018). 
Naringenin (4,5,7dihydroxy2(4hydroxyphenyl)2,3dihydrochromen4one), 
has a molecular weight of 272.257g/mol (Lin-Shiau et al., 2004). It falls under the subclass of 
flavanone, which is classified under the broad umbrella of flavonoids. It constitutes a 
common structure of two aromatic rings together with a linear 3-carbon chain (C6-C3-C6), 
forming an oxygenated heterocyclic nucleus. The hetrocycle in naringenin includes a 
saturated 3-carbon chain and an oxygen atom at carbon-4 (Kumar and Pandey, 2013) (Fig. 1). 
Naringenin is found in high concentrations, especially, in grapefruit (43.5 mg/100ml), 
followed by orange juice (2.13mg/100ml) and lemon juice (0.38mg/100ml) (Erlund, 2004; 
Gattuso et al., 2007) . Naringenin has been long investigated for its various pharmacological 
benefits. Its potential therapeutic effects include anti-inflammatory (Luo et al., 2012; Shi et 
al., 2015), antioxidant (Moon et al., 2011), anti-can er (Chang et al., 
2017), immunomodulatory (Du et al., 2009), hepatoprotective (Hermenean et al., 2014), 
nephroprotective (Borradaile et al., 2003), neuroprotective (Hartogh et al., 2019) and anti-
diabetic (Kumar et al., 2013; Nguyen-Ngo et al., 2019; Seyedrezazadeh et al., 2016). 
1.2.1. Bioavailability  
The large hydrophobic ring structure of naringenin co tributes to its low water solubility 
and minimal bioavailability. Kanaze and co-workers demonstrated that the oral 
bioavailability of naringenin is approximately 5.81%, when they administered 135mg 
naringenin in humans. (Kanaze et al., 2007). The absorption of naringenin occurs through 
both passive and active transport and the process is not affected by a change in pH (Garg et 
al., 2001; Justesen et al., 1998; Xu et al., 2009; Zhang et al., 2015).  
1.2.2. Anti-inflammatory properties  
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There is a strong published evidence to suggest the potential efficacy of flavonoids in 
inflammatory conditions, due to their wide range of mechanisms of action that work at the 
molecular level. At the early phase of inflammation, the pathogen- (PAMPs) and damage 
(DAMPs)-associated-molecular-patterns initiate the immune response. Resident macrophages 
generate more chemotactic molecules to attract leukocytes, mostly neutrophils. By generating 
superoxide anion, other ROS, along with nitrogen, neutrophils and activated macrophages 
eventually create oxidative stress. Naringenin inhibits the recruitment and the generation of 
superoxide anion (Manchope et al., 2016; Martinez et al., 2015), while increasing the ability 
of glutathione and antioxidants to quench free radic ls. Naringenin also acts on macrophages 
that induce activation of the nuclear factor erythroid 2-related factor 2 (Nrf2), a nuclear factor 
that induces antioxidant and anti-inflammatory reactions, resulting in the expression of 
hemeoxynase-1 (HO-1) (Manchope et al., 2016). PAMPs, DAMPs and ROS induce the 
activation of nuclear factor kappa-light-chain-enhacer of activated B cells (NFκB) in 
macrophages, which lead to the synthesis of pro-inflammatory cytokines such as interleukin 
(IL)-6, IL-8, IL-1β and tumour necrosis factor alpha (TNF-α). 
In addition, NF-κB activation has also been correlated with inflammatory activity in 
allergic airway illness (Hsu et al., 2017; Poynter et al., 2002). Naringenin has been proven to 
inhibit NF-κB activation in vitro (Conc. 30-1000nM) (Felipe A Pinho-Ribeiro et al., 2016) 
and in vivo (Conc. 50mg/kg) (Felipe A. Pinho-Ribeiro et al., 2016). NF-κB activation is 
widely implicated in inflammatory diseases (Chung, 2006). The inhibition of NF-κB pathway 
by naringenin is shown in Fig. 2.  
There are two different pathways for NF-κB activation, i) the canonical pathway and ii) 
the alternate pathway. Naringenin inhibits only the canonical pathway, which is initiated by 
microbial products and pro-inflammatory cytokines such as IL-1 and TNF-α (Lawrence, 
2009). This stimulation results in the activation of IκB kinase (IKK) complex (Ghosh and 
Karin, 2002), eventually phosphorylating the IKK β. The IKK complex then phosphorylates  
IκB that is bound to the p50/p65 subunits of NF-κB and inhibits its activity (Karin and Ben-
Neriah, 2000). The phosphorylated IκB undergoes ubiquitinylation followed by proteosomal 
degradation. This permits NF-κB to translocate to the nucleus which leads to its expression in 
the genes, causing inflammatory responses. Naringeni  may prevent degradation of IκB, 
thereby, inhibit NF-κB transcription activity (Lawrence, 2009).   




Asthma is a common airway inflammatory disease characte ized by increased 
inflammatory cells, mucus production, remodelling, and inflammatory mediators in the 
airway, which may cause impairment in the lung function (Hansbro et al., 2017; Kim et al., 
2020). In asthma, high oxidative stress stimulates intracellular signalling cascades. 
Inflammation is usually initiated via overexpression of pro-inflammatory markers which lead 
to expression of the inflammatory cytokines (Dua et l., 2019b; Liu et al., 2017). Such 
cytokines increase oxidative stress, stimulate immune responses, induce cytotoxicity, 
promote hyper-responsiveness of the bronchi, stimulate bronchospasm and also increase the 
secretion of mucin. The development of IgE has been correlated with the progression of 
asthma through interleukins, such as, IL-4 and IL-5. Besides, asthma induces oxidative stress 
due to a suppression in antioxidant defence mechanisms and an increase in ROS formation, 
that can lead to the damage of the lungs (Da Cunha et al., 2016; Fitzpatrick et al., 2012). 
Oxidative stress also induces mitochondrial dysfunctio  and inactivation of the electron 
transport chain in the lungs (Dua et al., 2019a; Mabalirajan et al., 2008; Silveira et al., 2019) 
(Fig. 3).  
Despite the morbidity and mortality rate of asthma being on the decreasing side, with the 
current therapies, poor responses towards corticosteroids were reported in 5–10 percent of 
asthma patients. Moreover, adverse effects resulting from excessive use of steroids have 
exerted a significant negative impact on the patients’ well-being. Consequently, there were 
also concerns that have been raised on the safety of prol nged use of corticosteroids (Silveira 
et al., 2019; Wadhwa et al., 2019b). However, recently reported evidence revealed the 
potential therapeutic effect of naringenin in experim ntal models of asthma (Guihua et al., 
2016; Kim et al., 2020).  
A study conducted by Ying et al., have reported that naringenin attenuated airway hyper-
reactivity (AHR) and airway inflammation in a murine model of asthma (Shi et al., 2009). 
The in vivo studies have shown reduced levels of IL-4 and IL-13 in bronchoalveolar 
lavage (BAL) fluid and total serum immunoglobulin E (IgE), after being treated with 
naringenin (25, 50, or 100mg / kg / body weight). In addition, pulmonary IκBα degradation 
and NF-κB DNA-binding activities have also been observed. Furthermore, naringenin 
significantly reduced the levels of chemokine (C-C motif) ligand 5 (CCL5), CCL11 and 
inducible synthase of nitric oxide (iNOS) (Shi et al., 2009). Theoretically, the inhibition of 




Further research by Ying and colleagues (2015) has s own that naringenin ameliorated 
chronic inflammation, continuous hyper-responsiveness and remodelling of the airways. 
Results revealed that the total T-helper 2 (Th2) cytokines, total serum and IgE levels in BAL 
fluid of mice had markedly reduced after the treatment with 50mg/kg dose of naringenin. 
This implies that naringenin may delay the airway remodelling progress (Shi et al., 2015).  
Interestingly, hyperplasia in the airway smooth muscle (ASM) was found to be associated 
with an increased severity of asthma (Haitchi et al., 2005; Ramos-Barbón et al., 2010; Wang 
et al., 2008). In accordance with previous reports, αSMA areas were drastically increased in 
animal models after exposure to ovalbumin, while naringenin treatment had successfully 
caused a reduction in ASM hyperplasia (Shi et al., 2009). A study by Shi et al., demonstrated 
a reduction in the resistance to airflow in respiratory tract after treatment with naringenin (Shi 
et al., 2015). As ASM contributes to the narrowing of the airways along with airway hyper-
reactivity, it is presumed that naringenin could have reduced the thickness of the ASM layer 
and could have ameliorated AHR. 
Furthermore, Seyedrezazadeh et al., attempted to critically examine the anti-inflammatory 
potential of flavonoids (hesperitin and naringenin) o  asthma. The study revealed that 
inflammation and remodelling of the airways in murine chronic asthma models were 
markedly reduced after hesperetin-naringenin treatmn . Histopathological examination 
highlighted the absence of goblet cells metaplasia  well as decreased intra-alveolar 
macrophages upon treatment with hesperetin-naringeni . This study also confirmed that the 
combination of hesperetin-naringenin led to the reduction in sub-epithelial fibrosis, 
hypertrophy of smooth muscle in airways, and atelecasis of lungs. These findings suggest 
that naringenin may ameliorate airway structural remodelling, which contributes to the 
treatment of asthma (Seyedrezazadeh et al., 2015). 
Moreover, Iwamura et al., reported that the oral administration of naringenin chalcone 
significantly reduced Th2 production from the splenic cluster-of-differentiation-4 (CD4) T 
cells without affecting its proliferative ability (Iwamura et al., 2010). Total cell counts of 
infiltrating leukocytes decreased in mice with narigenin treatment. It is well known that IL-
13 causes hyper-responsiveness in the airways and produces mucus in the absence 
of inflammatory cells (Wills-Karp, 1999). These symptoms are very typical of asthma and are 
further attributed to its fatality. IL-4, in addition, stimulates mucus production. IL-5 is known 
to improve the survival of eosinophils (Rothenberg and Hogan, 2006). The study 
also reported a reduction in the hyperproduction of mucus and cytokines (IL-4, IL-5, IL-13).  
Naringenin-chalcone may have inhibited the type I allergic reaction by suppressing the 
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production of histamine from mast cells. However, the mechanisms employed in the 
suppression of Th2 production by CD4 T cells and the dysregulation by mast cells are not 
fully known. More studies are needed to further explain the various mechanisms of action. 
Therefore, naringenin-chalcone could be proposed as a substitute for asthma treatment 
(Iwamura et al., 2010). 
Moreover, thymic stromal lymphopoietin (TSLP) is known to play a vital role in allergic 
diseases. In a study conducted by Moon et al., he findings demonstrated that the synthesis 
and expression of TSLP in HMC-1 cells were inhibited with naringenin treatment (Moon et 
al., 2011). Naringenin (100μM) inhibited TSLP production at a maximal rate of 
62.27±10.79%. Naringenin also reduced the NF-κB luciferase activity (Moon et al., 2011). 
These findings suggest that naringenin may inhibit TSLP production and therefore, could be 
useful in the treatment of inflammation and allergic diseases (Table 1). 
  
2.2. Chronic Obstructive Pulmonary Disease (COPD) 
Chronic Obstructive Pulmonary Disease (COPD) is a serious public health burden and is 
prevalent in smokers (Chellappan et al., 2020; Luo et al., 2012; Zaidun et al., 2018). The 
inflammation in COPD is known to be mediated by several factors such as pro-inflammatory 
cytokines, glucocorticoid receptor (GR) and NF-κB. Patients with COPD have been reported 
to respond poorly to corticosteroid therapy (Barnes, 2013; Wadhwa et al., 2019a).  
Naringenin is thought to be beneficial in COPD due to its anti-inflammatory properties. A 
study carried out by Liu et al., investigated the effects of naringenin in both, laboratory-bred 
strain (BALB/c) mouse model induced with COPD using cigarette smoke (CS) and also with 
an in vitro model using A549 cells (Liu et al., 2018). The animals were pre-treated with 
naringenin in doses of 20, 40 and 80 mg/kg concentration, whereas, the in vitro cells were 
treated with naringenin along with CS extract exposure. Naringenin was found to 
significantly improve the pulmonary function, decreas  inflammatory cells, and inhibit the 
pro-inflammatory cytokine production in BAL fluid and serum of CS animal group. 
Naringenin also inhibited the NF-κB pathway as revealed by reduced phosphorylation of NF-
κB and IκB (Hämäläinen et al., 2007; Hua et al., 2016; Kumar R. and Abraham, 2017; Liu et 
al., 2018). Moreover, the levels of GR mRNA and protein were also significantly increased 
upon treatment with naringenin both in CS-exposed anim ls and cell culture. Therefore, 
naringenin could be an ideal therapeutic agent in ameliorating COPD-related inflammation 
(Liu et al., 2018). 
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Mucus hypersecretion is one of the common symptoms a ong COPD patients. In most of 
the cases, it is due to enlarged submucosal glands  an increased number of goblet cells in 
response to chronic airway irritation (Vestbo et al., 2013).  A study conducted by Yang et al., 
related naringenin with mucus hypersecretion. It was found that naringenin reduced mucus 
hypersecretion by inhibiting the development of ROS and down-regulating NF-κB pathway 
via EGFR-PI3K-Akt / ERK MAPKinase signalling in the epithelial cells of human airways 
(Yang et al., 2011).  
A further study conducted by Lin et al., revealed that naringenin exhibited an expectorant 
behaviour in the in vivo models. Naringenin (90 mg/kg) reduced the viscosity of mucus, 
which is caused by an increased airway volume secretion. This resulted in an improved 
mucus removal from the airway. In addition, the elevat d airway secretion volume was 
attributed to the increased secretion of lysozyme (Lin et al., 2008). Moreover, naringenin also 
reduced the mucin secretion. These activities demonstrated naringenin’s promising 
therapeutic benefits in ameliorating respiratory mucus hypersecretion (Table 1).  
 
2.3. Lung cancer 
Lung cancer is predominantly caused by long term exposures to carcinogens such as 
tobacco-smoke or inorganic agents, which manifest their carcinogenic effects primarily 
through oxidative stress (Finocchiaro et al., 2014; Sharma et al., 2019). Chronic and 
cumulative oxidative stress can cause continuous and sustained pulmonary inflammation 
which plays a vital role in cancer initiation and progression. Bodduluru et al., reported the 
chemopreventive effects of naringenin (50mg/kg). The study reported the suppression of 
oxidative stress, inflammatory and cell proliferation in benzo(a)pyrene (B[a)P) induced lung 
cancer bearing mice. The antioxidant and free-radical s avenging activity of naringenin is 
observed through a decreased lipid peroxidation by enhanced activity of enzymatic 
antioxidants, namely, glutathione peroxidase (GPx), catalase (CAT), glutathione-S-
transferase (GST), superoxide dismutase (SOD) and glutathione reductase (GR), in addition 
to non-enzymatic antioxidants like vitamin C and glutathione (GSH) Moreover, naringenin 
ameliorated inflammatory response through the down regulation of NF-κB and subsequently 
reduced the levels of inflammatory cytokines, namely, TNF-α, IL-Iβ and IL-6. Besides, 
decreased expression levels of proliferating cell nuclear antigen (PCNA) and CYP1A1 upon 
naringenin treatment have demonstrated the capability of naringenin in inhibiting cancer 
initiation and cell proliferation respectively (Bodduluru et al., 2016). Tundis et al., in their 
10 
 
study, also demonstrated that naringenin, which was isolated from Salvia leriifolia ethyl 
acetate extract, exhibited selective antiproliferative activity against human lung large cell 
carcinoma (COR-L23). Interestingly, naringenin (IC50 values of 33.4 µM) showed more 
potent antitumor properties compared to a Vinca alkloid, vinblastine (IC50 values of 50.0 
µM) (Tundis et al., 2011).  
Metastasis remains a major contributing factor to po r prognosis and survival in lung 
cancer patients (Sangodkar et al., 2010). Chang et al., suggested that, treatment with 200 and 
300µM naringenin for 48h markedly inhibited lung can er A549 cells migration. Naringenin 
has shown to downregulate metalloproteinase (MMP)-2 and -9 proteolytic activity in the 
degradation of extracellular cell matrix. This, in particular, led to the inhibition of cancer cell 
invasion into the circulation. In addition, naringein also intercepted the migration of A549 
cells, via attenuation of AKT activities (Chang et al., 2017).  
In addition, resistance to chemotherapy is also one of the major obstacles to treat lung 
cancer effectively. Interestingly, naringenin has been reported to enhance the anticancer 
effect of chemotherapeutic agents and thereby, sensitize the drug-resistant cancer cells to 
chemotherapy. It has also been reported that resistance to tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) treatment has been d monstrated in human non-small-
cell lung cancer (NSCLC) cell line A549 (Zhuang et al., 2010). TRAIL is a potent apoptosis 
inducing cytokine which selectively kills cancer cells over normal cells upon binding with the 
death receptor 4 (DR4) and DR5. Previous findings revealed that poor expression and 
functional signalling of DRs could contribute to TRAIL resistance in tumour cells (Zhang 
and Fang, 2005). A recent study by Jin et al., showed that co-treatment with naringenin (100 
µM) and TRAIL specifically induced and enhanced the activity of TRAIL-mediated 
apoptosis by upregulating DR5 expression in TRAIL-resistant A549 cells, which further 
induced caspase-8 and the cleavage of BH3 protein Bid (Jin et al., 2011). Furthermore, 
resistance to gefitinib, a first line agent in treaing metastatic NSCLC has emerged in most of 
the patients and has caused death due to cancer metastasis from the resistant tumour cells (Qi 
et al., 2018). Li et al., suggested that Four Gentlemen Decoction, a Chinese poly-herb 
formulation which contains naringenin as one of the major components, has shown to 
enhance anti-cancer activity of gefitinib and inhibit metastasis in mice bearing lung cancer. 
Naringenin acted on multi-drug resistance-associated protein 1 (ABCC1), glutathione 
reductase (GSR) and 4-aminobutyrate aminotransferase (ABAT) which regulated taurocholic 
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acid, oxidized glutathione and oxygultaric acid respectively. Thereby, it was suggested that 
naringenin can alleviate TRAIL and gefitinib resistance (Li et al., 2019).  
Instead of targeting tumour cells as treatment of lung cancer, Lian et al., reported that the 
combined use of naringenin and asiatic acid (AA), a natural herb-derived compound, has 
shown to be a promising immunotherapy, that acts by targeting the tumour 
microenvironment. Transforming growth factor β1 (TGF-β1) promotes tumour growth and 
supresses immune system through down-regulation of Smad7 and hyper-activation of Smad3 
signalling in the tumour microenvironment. Naringenin (50mg/kg) acted as a Smad3 inhibitor 
whereas, AA (10mg/kg) acted as a Smad7 inducer in regulating Smad3/Smad7 signalling to 
suppress tumour progression by inducing cytotoxicity against cancer cell production and 
natural killer (NK) cell production in tumour-bearing mice. The Down-regulation of TGF-β1-
mediated inhibition of Id2/IRF2 is believed to be accountable for the elevated NK cell 
production (Lian et al., 2018) (Table 1).   
 
2.4. Pulmonary fibrosis 
Pulmonary fibrosis (PF) is characterized by chronic and progressive tissue repair 
responses that lead to excessive accumulation of extracellular matrix (ECM) and remodelling 
of the lung (Dua et al., 2018a; Kolahian et al., 2016). Recent studies have identified that 
naringenin exerted antifibrotic properties, as a potential agent to alleviate PF which is 
triggered by infection, radiotherapy, environmental and occupational pollutants.  
TGF-β is a major pro-fibrotic mediator which mainly is involved in pulmonary fibrosis, 
by promoting ECM accumulation. Du et al., reported that oral administration of naringenin at 
100mg/kg/day inhibited the pro-fibrotic activity inbleomycin-induced murine models of PF, 
through a reduction in the level of TGF- β1, which further led to decreased CD4+ 
CD25+Foxp3+ regulatory T cells (Du et al., 2009; Saito et al., 2018).  
IL-1β is a proinflammatory cytokine that has been shown to contribute to PF progression 
(Kolb et al., 2001). Zhang and co-workers demonstrated that naringenin exerted protective 
effect in radiation-induced lung injury. The production of IL-1β was reduced upon treatment 
with naringenin and it has shown a similar efficacy with IL-1β neutralizing antibody in mice 
that received irradiation. Interestingly, naringenin was able to restore the homeostasis of 
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irradiation-induced inflammatory factors by recovering 22 inflammatory factors to normal 
levels in the unaffected rats (Zhang et al., 2018).  
The induction of pulmonary fibrosis in pneumonia caused by Mycoplasma pnemoniae 
(MP) is associated with elevated pro-inflammatory cytokines through autophagy (Shimizu, 
2016). Lin et al., conducted a study in MP infected mice, which showed significant inhibition 
of inflammatory mediators (IL-Iβ, IL-6, and TNF-α) and TGF-β expression upon 
administration of naringenin at 100mg/kg/day. The mechanism involved in reversing MP-
induced inflammatory response and PF was demonstrated by inhibiting autophagy-related 
protein Beclin-1 and LC3 in addition with reducing expression of p62 (Lin et al., 2018).  
Studies have provided sufficient evidence that naringenin exhibits a protective action 
against occupational exposure and hazardous agents that cause fibrotic lung damage. 
According to a study done by Ali et al., naringenin given at a dose 100mg/kg/day alleviated 
inflammation and oxidative stress in B[a]P-induced rats (Ali et al., 2017). Naringenin 
suppressed the expression of COX-2 through down-regulation of NF-κB which led to 
decreased inflammatory response. Furthermore, naringen  treatment also attenuated B[a]P-
induced oxidative stress by enhancing the activity of antioxidant enzymes (CAT, SOD, GST, 
GPx, GR and GSH) and suppressing ROS-mediated damage in lung tissues. A study 
conducted by Podder et al., on paraquat-exposed human bronchial epithelial BEAS-2B cells, 
demonstrated that naringenin at 100µM exerted cytopro ective effect via upregulation of Nrf2 
antioxidant pathway. Nrf2 further activated its downstream antioxidant proteins HO-1 and 
NAD(P)H:quinone oxidoreductase 1 (NQO1) (Podder et al., 2014) (Table 1).     
2.5. Cystic fibrosis 
Cystic fibrosis (CF) is a progressive inherited disorder which is attributed to the 
mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, that causes 
build-up of abnormally thick, sticky mucus linings in the lungs (Rowe et al., 2005). 
Nonetheless, there is currently no cure for CF. However, treatments are available to slow 
down lung disease as much as possible. A study by Shi et al., showed that naringenin (50µM 
and 100 µM) enhanced CFTR mRNA expression in LPS-induced CFTR down-regulated 
Calu-3 cells (Shi et al., 2017). Increased CFTR expr ssion via cAMP pathway stimulated Cl -
secretion, resulted in improved electrolyte and fluid secretion that led to the removal of 
sputum from the airway. The expectorant function of aringenin might be a promising 







3. Clinical trials involving Naringenin 
There are very few clinical trial studies on potential therapeutic outcomes with naringenin, 
and no clinical studies have been carried out yet on the anti-inflammatory effect of 
naringenin in airway inflammatory diseases (Salehi et al., 2019). 
Till date, there are only 8 clinical trials in the entire database that were conducted using 
naringenin, which have been successfully registered at clinicaltrials.gov. The focus areas 
include, hepatitis, safety, pharmacokinetics of naringenin, bioavailability of naringenin and 
vascular protection effect of naringenin (“A Pilot Study of the Grapefruit Flavonoid 
Naringenin for HCV Infection - Full Text View - Clin calTrials.gov,” n.d.). The clinical trial 
data with the ClinicalTrials.gov identifier (NCT03582553) evaluated the safety and 
pharmacokinetics of naringenin in healthy adults using an entire orange extract (Citrus 
sinensis). Results showed that, intake of naringenin at dose of 150mg to 900mg is safe in 
healthy adults. Serum levels were proportional to the dose given (“Safety and 
Pharmacokinetics of an Extract of Naringenin - Full Text View - ClinicalTrials.gov,” n.d.).   
Most clinical studies investigated naringenin along with a complex food, instead of pure 
naringenin. For instance, whole orange juice which constitutes several polyphenols was 
studied instead of naringenin alone. This led to the difficulty in assessing the contribution of 
the single phytochemical (“Bioavailability of Carotenoids and Flavonoids From Fresh 
Oranges and Orange Juice. - Full Text View - ClinicalTrials.gov,” n.d.; Silveira et al., 2014). 
Clinical trials on naringenin to justify its anti-inflammatory effect in airway inflammatory 
diseases are highly recommended, as naringenin has been proven for its anti-inflammatory 
effect in both in vivo and in vitro studies. Thus, naringenin could be an alternative to the 
conventional treatment of airway inflammatory diseases (Salehi et al., 2019). 
 
4. Drug delivery systems of naringenin 
The poor aqueous solubility and minimal bioavailability of naringenin, owing to its large 
hydrophobic ring structure remains a major concern despite its promising therapeutic benefits. 
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Several studies have utilised nanocarriers as drug elivery system for naringenin in order to 
modulate its pharmacokinetics and pharmacodynamics profile, thus enhancing the therapeutic 
index of the drug. The reported drug delivery systems of naringenin and their key outcomes 
are summarized in Table 2.  
 
4.1. Polymeric nanoparticles 
Polymeric nanoparticles (NPs) are colloidal-shaped solid particles made of biodegradable 
and biocompatible polymers or copolymers, in which the drug can be encapsulated with the 
carrier (Dua et al., 2018b; Wadhwa et al., 2019c). The polymers that are commonly used to 
synthesise polymeric NPs include natural polymers such as alginate, chitosan, and gelatin in 
addition to synthetic polymers such as poly(lactide-co-glycolide) copolymers (PLGA), 
poly(lactide) (PLA), polyvinylpyrrolidone (PVP) and poly(ε-caprolactone) (PCL). 
Kumar and coworkers studied on the anti-inflammatory and antioxidant activities of PVP-
coated NPs on lipopolysaccharide induced RAW264.7 cell lines. The formulation was 
prepared by nanoprecipitation technique with an entrapment efficiency of 99.93% (Kumar 
and Abraham, 2016). PVP coated-naringenin NPs were found to be non-cytotoxic at any 
concentration below 200ug/mL. Furthermore, the anti-inflammatory effect in PVP-coated 
naringenin NPs has been found to be more pronounced, when compared to pure naringenin. 
Formulated naringenin has shown to suppress the inflammatory activities through down 
regulation of NF-κB via P38MAPK signaling pathways. This resulted in COX-2 and iNOS 
blockade, and thereby inhibited the inflammatory mediators (IL-6, IL-1β, TNF-α and MCP-1) 
and nitric oxide production (Kumar R. and Abraham, 2017). 
Kumar et al., also reported that encapsulation of naringenin into chitosan NPs (CS-NPs) 
demonstrated improved antioxidant and anticancer activities of naringenin in A549 lung 
cancer cells. Naringenin-CS-NPs was prepared by ionic gelation method mediated by 
tripolyphosphate as a cross linker. The nanoparticles demonstrated an entrapment efficiency 
of approximately 70-80%. Cytotoxic test suggested that naringenin-CS-NPs exhibited 
selective cytotoxic effect against A549 cells. Moreov r, the free radical scavenging activity 
in naringenin-CS-NPs is significantly higher than pure naringenin. Formulated naringenin is 
capable to inhibit hydroxyl radical, react with nitric oxide to inhibit production of nitrites and 
reduce the DPHH radical to non-radical form (Kumar et al., 2015). 
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Polymeric NPs such as PCL lack of target specificity, hence surface modification with 
specific ligands was attempted for tumour targeting (Cabeza et al., 2017). Parteek et al., 
showed that co-administration of biotin decorated polymeric nanoparticles of naringenin and 
gefitinib, enhanced the therapeutic efficacy and antitumor effect in lung cancer both in vitro 
and in vivo. The biotin-conjugated PCL-PEG NPs were synthesised u ing oil in water 
emulsion method. It showed minimal toxicity and facilitated targeted drug delivery to tumor 
cells. Co-administration of gefinitib and naringenin NPs promoted enhanced cell apoptosis 
while regulating the serum metabolites and biochemical parameters to normal levels. The co-
therapy caused a remarkable increase in the pro-apoptotic proteins (BAX and caspase-9) and 
reduced anti-apoptotic proteins (MMP-9, P-16 and Bcl-2) (Parashar et al., 2018b). Parteek 
and coworkers also indicated that, entrapment of naringenin into hyaluronic acid-chitosan-
PCL NPs, by utilizing layer by layer technique, is effective in targeting lung cancer cells. 
Cytotoxic study of the formulated naringenin on A549 cells depicted selective and enhanced 
anticancer effects. Increased drug uptake by cancer cells has been shown with formulated 
naringenin, in addition to active targeting and enhanced cytotoxic effect (Parashar et al., 
2018a).   
4.2. Solid lipid nanoparticles 
Solid lipid nanoparticles (SLNs) are lipid-based drug delivery systems that are produced 
from solid lipid matrix which are stabilized with no toxic emulsifiers (Mehta et al., 2014; 
Naahidi et al., 2013). The solid lipid matrix can protect drug molecules against chemical 
degradation. Ji et al., demonstrated that naringenin SLNs possessed sustained drug release 
activity with enhanced stability and increased bioavail bility upon pulmonary administration. 
Naringenin was incorporated into SLNs by emulsification and low-temperature solidification 
method using glycerol monostearate as solid lipid matrix. Naringenin-SLNs was reported to 
have an entrapment efficiency of 79.11% with sustained drug release properties. 
Furthermore, studies in A549 cells demonstrated that naringenin-SLNs were non-toxic. Upon 
administration of naringenin-SLNs via pulmonary instillation in rats, the findings indicated 
that the relative bioavailability was 2.53-fold great r compared to pure naringenin treatment 







Several studies have demonstrated the clinical potential of naringenin in regulating 
various biochemical pathways in airway inflammatory diseases by both preventive and 
therapeutic measures. Despite evidences proving that naringenin could offer a novel strategy 
on chronic respiratory disease, the available data on safety and efficacy in human studies 
remain limited due to its poor aqueous solubility and minimal bioavailability. Further studies 
in developing optimal drug delivery system are needed to better address the bioavailability, 
efficacy and safety of naringenin.  
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Fig. 1. The chemical structure of naringenin 
 
Fig. 2. Cellular/molecular mechanisms and pathways involved in inflammation through 
inhibition of NF-κB by naringenin 
 
Fig. 3. Summary of the therapeutic effects of naringenin i chronic inflammatory diseases 
and their (*In-vitro/#In-vivo) mechanisms 





Study model / 
subject 
Dose Findings Ref. 
Asthma In vivo Female 
BALB/c mice 
25, 50, or 
100mg/kg 
Attenuated airway inflammation and 
AHR. 
(45) 
In vivo Female 
BALB/c mice 
50mg/kg i.p. Decreased total serum Th2 and IgE 
cytokines in BAL fluid and slowed 
down the progression of airway 
remodelling. 
(17) 
In vivo Male BALB/c 
mice 
9mg/100ml Histopathological examination 
highlighted absence of goblet cells 
metaplasia, decreased intra-alveolar 
macrophages, sub-epithelial fibrosis, 
smooth muscle hypertrophy in 
airways and lung atelectasis 
(49) 
In vivo BALB/c mice  0.8 mg/kg p.o. Attenuated AHR, eosinophilic 
airway inflammation and Th2 
cytokine production.  
(50) 
In vitro HMC-1 cell 
line 
100µM Regulated the inflammatory 
responses in mast cells.  
Inhibited TSLP production through 
the inhibition of RIP2/caspase-1 as 
well as NF-κB pathway. 
(44) 
COPD In vivo  BALB/c mice  20, 40 and 80 
mg/kg 
Improved the pulmonary function 
and attenuated the inflammation in 
the lung tissues. 
Inhibited IL-8, TNF-α, and MMP9 
significantly. 
Decreased NF-κB p65 and IκB-α 
phosphorylation and improved GR 
level. 
(53) 
In vitro A549 cell line 2, 20 and 
50mM 
Inhibited IL-8, 
TNF-α and MMP9 expression. 
Upregulated GR expression. 
(53) 






female SD rats  
 
90mg/kg Enhanced removal of mucus through 
increased airway volume secretion 
and  




In vivo Male Swiss 
albino mice 
50mg/kg Decreased level of lipid 
peroxidation. 
Enhanced enzymatic and non-
enzymatic antioxidants. 
(61) 
Down-regulated NF-κB and reduced 
TNF-α, IL-1β and IL-6 expression. 
Down-regulated CYP1A1 and 
PCNA. 
In vitro COR-L23 cell 
line 
33.4µM Exhibited more potent anti-tumor 
activity than vinblastine.  
(62) 
In vitro A549 cell line 25 - 300µM Reduced AKT activities  
Down-regulated MMP-2 and MMP-9 
activities. 
(19) 
In vitro A549 cell line 100 µM Enhanced the activity of TRAIL-





In vivo Male 
C57BL/6 J 
mice  
Not available  Enhanced anti-cancer efficacy of 
gefitinib and inhibited lung 
carcinoma metastasis. 
(68) 
In vivo C57BL/6 mice 50mg/kg Suppressed lung carcinoma growth 











100mg/kg Inhibited profibrotic activity by 














Wistar rats  
100 mg/kg and 
200 mg/kg 
  
Ameliorated RILI through down-
regulation of IL-1β and maintained 












Inhibited IL-6, IL-1β, TNF-α and 
TGF- β expression. 
(76) 
In vivo Male Wistar 
rats 
100mg/kg Suppressed COX-2 expression 
through down-regulation of NF- κB 
pathway. 
Enhanced activity of antioxidant 
enzymes. 
(77) 
In vitro  BEAS-2B cell 
line 
 
5 - 100µM 
 
Exerted cytoprotective effect via 
modulation of Nrf2-mediated 




In vitro Calu-3 cells 50µM and 100 
µM 






















In vivo, male 
Sprague Dawley 
rats 
Down regulated NF-kB expression 
via P38MAPK signaling pathways.  
Inhibited iNOS and COX-2 and 
reduced levels of TNF-α, IL-6, 
MCP-1 and IL-1β.  
Nanoparticles were nontoxic. 
Nanoparticles exerted enhanced 








In vitro, A549 
cell line  
Inhibited production of hydroxyl 
radical, nitrites and DPHH radical. 
Exhibited cytotoxic effect towards 
A549 cells only. 
Improved antioxidant and anticancer 




















Up-regulated pro-apoptotic proteins 
(caspase-9 & BAX) and down-
regulated anti-apoptotic proteins (P-
16, MMP-9 & Bcl-2). 
Reported minimal toxicity and 
facilitated targeted drug delivery. 















In vitro, A549 






Possessed sustained drug release and 
increased tumor targeting.  
Exhibited cytotoxic effect towards 
A549 cells only. 












In vivo, male 
Sprague Dawley 
rats 
Possessed sustained drug release, 
with enhanced stability and 
increased bioavailability. 
Nanoparticles were nontoxic. 
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